HK1101140A1 - Compositions and methods for treating neurological disorders - Google Patents

Compositions and methods for treating neurological disorders

Info

Publication number
HK1101140A1
HK1101140A1 HK07109272.3A HK07109272A HK1101140A1 HK 1101140 A1 HK1101140 A1 HK 1101140A1 HK 07109272 A HK07109272 A HK 07109272A HK 1101140 A1 HK1101140 A1 HK 1101140A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
neurological disorders
treating neurological
treating
Prior art date
Application number
HK07109272.3A
Other languages
English (en)
Inventor
Dan Frenkel
Ruth Maron
David Burt
Howard L Weiner
Original Assignee
Id Biomedical Corp Quebec
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec, Brigham & Womens Hospital filed Critical Id Biomedical Corp Quebec
Publication of HK1101140A1 publication Critical patent/HK1101140A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK07109272.3A 2004-06-25 2007-08-27 Compositions and methods for treating neurological disorders HK1101140A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58299904P 2004-06-25 2004-06-25
PCT/US2005/022922 WO2006004749A2 (en) 2004-06-25 2005-06-27 Compositions and methods for treating neurological disorders

Publications (1)

Publication Number Publication Date
HK1101140A1 true HK1101140A1 (en) 2007-10-12

Family

ID=35207559

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109272.3A HK1101140A1 (en) 2004-06-25 2007-08-27 Compositions and methods for treating neurological disorders

Country Status (18)

Country Link
US (1) US20060229233A1 (ru)
EP (3) EP1761276B1 (ru)
JP (2) JP5274011B2 (ru)
KR (2) KR101347105B1 (ru)
CN (2) CN101039691B (ru)
AU (1) AU2005259991B2 (ru)
CA (1) CA2571035A1 (ru)
ES (1) ES2432369T3 (ru)
HK (1) HK1101140A1 (ru)
IL (1) IL179933A (ru)
MA (1) MA28975B1 (ru)
MX (1) MXPA06015096A (ru)
NO (1) NO20070460L (ru)
NZ (2) NZ578727A (ru)
RU (2) RU2387453C2 (ru)
SG (2) SG186686A1 (ru)
WO (1) WO2006004749A2 (ru)
ZA (1) ZA200610661B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173140B2 (en) 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP1957082B1 (en) * 2005-12-02 2012-04-11 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
US7629135B2 (en) * 2006-12-22 2009-12-08 The Board Of Trustees Of The University Of Illinois Toll-like receptor agonists and antagonists and methods of use thereof
EP2185160B1 (en) 2007-08-31 2019-02-13 Neurimmune Holding AG Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
MX2010003548A (es) * 2007-10-01 2010-06-02 Univ Johns Hopkins Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
CA2722558A1 (en) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions
WO2009146301A1 (en) * 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
EP2405749B1 (en) * 2009-08-20 2013-05-08 Yeda Research and Development Co., Ltd. Low frequency glatiramer acetate therapy
KR101692097B1 (ko) 2010-03-31 2017-01-02 톰슨 라이센싱 비디오 데이터의 트릭 재생
US9510758B2 (en) 2010-10-27 2016-12-06 The General Hospital Corporation Apparatus, systems and methods for measuring blood pressure within at least one vessel
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
JP2019519515A (ja) 2016-05-20 2019-07-11 シーダーズ—シナイ メディカル センター アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法
RU2629385C1 (ru) * 2016-09-29 2017-08-29 Владимир Федорович Корсун Способ лечения рассеянного склероза
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
BR9506885A (pt) * 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
PL325604A1 (en) 1995-09-18 1998-08-03 Us Army Med Res Mat Command Improved methods of obtaining non-covalently complexed and multvalent proteosomal subunitary vaccines
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2000154148A (ja) * 1998-11-20 2000-06-06 Toray Ind Inc インターフェロンβをアジュバントとするワクチン
IL142948A0 (en) * 1999-09-03 2002-04-21 Univ Ramot Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
EP1255561B1 (en) * 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteosome influenza vaccine
AU2001238469C1 (en) * 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
KR20080017471A (ko) * 2000-02-21 2008-02-26 파멕사 에이/에스 아밀로이드의 하향-조절을 위한 신규한 방법
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
US8173140B2 (en) * 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
RU2007103343A (ru) * 2004-06-30 2008-08-10 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК (CA) Вакцинная композиция и способы лечения коронавирусной инфекции
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof

Also Published As

Publication number Publication date
JP2012041351A (ja) 2012-03-01
IL179933A0 (en) 2007-05-15
WO2006004749A2 (en) 2006-01-12
CN101039691B (zh) 2013-07-31
WO2006004749A3 (en) 2006-04-20
ZA200610661B (en) 2008-08-27
RU2007102698A (ru) 2008-07-27
AU2005259991A1 (en) 2006-01-12
JP2008504299A (ja) 2008-02-14
NZ578727A (en) 2011-03-31
ES2432369T3 (es) 2013-12-03
EP2332569A2 (en) 2011-06-15
EP1761276A2 (en) 2007-03-14
US20060229233A1 (en) 2006-10-12
NZ552075A (en) 2009-08-28
EP1761276B1 (en) 2013-07-24
KR101347105B1 (ko) 2014-01-02
RU2010103240A (ru) 2011-08-10
AU2005259991B2 (en) 2011-05-26
JP5274011B2 (ja) 2013-08-28
EP2332570A1 (en) 2011-06-15
KR101347562B1 (ko) 2014-01-03
EP2332569A3 (en) 2011-09-14
KR20120112885A (ko) 2012-10-11
CA2571035A1 (en) 2006-01-12
IL179933A (en) 2015-06-30
MA28975B1 (fr) 2007-11-01
SG153871A1 (en) 2009-07-29
CN103143011A (zh) 2013-06-12
RU2387453C2 (ru) 2010-04-27
CN101039691A (zh) 2007-09-19
KR20070048703A (ko) 2007-05-09
MXPA06015096A (es) 2007-05-09
NO20070460L (no) 2007-03-23
SG186686A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
HK1101140A1 (en) Compositions and methods for treating neurological disorders
ZA200700918B (en) Compositions and methods for treating eye disorders and conditions
IL180187A0 (en) Compositions and methods for treating inflammatory disorders
EP1651164A4 (en) COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL179766A0 (en) Compositions and methods using same for treating neurodegenerative disorders
GB2423928B (en) Methods and compositions for treating pain
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
AU2006279280A8 (en) Methods and compositions for treating neurological disease
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL187480A0 (en) Method and composition for treating inflammatory disorders
EP1680009A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF MENTAL ILLNESSES
HK1121952A1 (en) Methods and compositions for treating conditions
PT2374472T (pt) Composições e métodos para o tratamento de afeções oftalmológicas
IL183985A0 (en) Methods for treating autoimmune disorders
HK1157575A1 (en) Treating neurological disorders
IL186963A0 (en) Methods and compositions for treating pain
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
IL191168A0 (en) Compositions and methods for treating cns disorders
HK1118716A1 (en) Method and composition for treating central nervous system disorders
EP1898921A4 (en) COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS
EP1755637A4 (en) METHODS FOR PREVENTING OR TREATING BONE DISEASES
EP1844009A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
AU2003297259A8 (en) Methods and compositions for treating neurological disorders